These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32369690)

  • 1. Antipsychotic Polypharmacy in Schizophrenia: Why Not?
    Guinart D; Correll CU
    J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32369690
    [No Abstract]   [Full Text] [Related]  

  • 2. Antipsychotic polypharmacy: are two ever better than one?
    Goff DC; Dixon L
    Am J Psychiatry; 2011 Jul; 168(7):667-9. PubMed ID: 21724670
    [No Abstract]   [Full Text] [Related]  

  • 3. Monotherapy versus polypharmacy for hospitalized psychiatric patients.
    Strous RD; Lerner V
    Am J Psychiatry; 2005 Mar; 162(3):631-2; author reply 632-3. PubMed ID: 15741496
    [No Abstract]   [Full Text] [Related]  

  • 4. Measuring efficacy of polypharmacy in schizophrenic inpatients.
    Lindenmayer JP
    J Clin Psychiatry; 2004 Aug; 65(8):1148; author reply 1148. PubMed ID: 15323607
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.
    Ganguly R; Kotzan JA; Miller LS; Kennedy K; Martin BC
    J Clin Psychiatry; 2004 Oct; 65(10):1377-88. PubMed ID: 15491242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
    Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
    JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic polypharmacy is not associated with reduced dose of individual antipsychotics in schizophrenia.
    John AP; Dragovic M
    J Clin Psychopharmacol; 2015 Apr; 35(2):193-5. PubMed ID: 25679123
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging guidelines for the use of antipsychotic polypharmacy.
    Stahl SM
    Rev Psiquiatr Salud Ment; 2013; 6(3):97-100. PubMed ID: 23485567
    [No Abstract]   [Full Text] [Related]  

  • 9. Antipsychotic polypharmacy: never say never, but never say always.
    Stahl SM
    Acta Psychiatr Scand; 2012 May; 125(5):349-51. PubMed ID: 22506490
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.
    Yamanouchi Y; Sukegawa T; Inagaki A; Inada T; Yoshio T; Yoshimura R; Iwata N
    Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25522380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment?
    Correll CU
    J Clin Psychiatry; 2008 Apr; 69(4):674-5. PubMed ID: 18507487
    [No Abstract]   [Full Text] [Related]  

  • 12. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia.
    Suzuki T; Uchida H; Tanaka KF; Nomura K; Takano H; Tanabe A; Watanabe K; Yagi G; Kashima H
    Int J Neuropsychopharmacol; 2004 Jun; 7(2):133-42. PubMed ID: 14741059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia.
    Xiang YT; Weng YZ; Leung CM; Tang WK; Ungvari GS
    Pharmacopsychiatry; 2007 Mar; 40(2):47-52. PubMed ID: 17447172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ; Andel R; McPherson M; Tandon R
    Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia.
    Suzuki T; Uchida H; Tanaka KF; Tomita M; Tsunoda K; Nomura K; Takano H; Tanabe A; Watanabe K; Yagi G; Kashima H
    Int Clin Psychopharmacol; 2003 Nov; 18(6):323-9. PubMed ID: 14571152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy versus polypharmacy for hospitalized psychiatric patients.
    Citrome L; Jaffe A; Levine J
    Am J Psychiatry; 2005 Mar; 162(3):631; author reply 632-3. PubMed ID: 15741497
    [No Abstract]   [Full Text] [Related]  

  • 18. Antipsychotic polypharmacy: do benefits justify the risks?
    Tapp AM; Wood AE; Kilzieh N; Kennedy A; Raskind MA
    Ann Pharmacother; 2005 Oct; 39(10):1759-60. PubMed ID: 16144885
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia - a pooled analysis.
    Lin CH; Wang FC; Huang YH; Lin SC; Kuo CC
    CNS Spectr; 2019 Dec; 24(6):632-633. PubMed ID: 31084636
    [No Abstract]   [Full Text] [Related]  

  • 20. Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014.
    Fontanella CA; Hiance-Steelesmith DL; Guirgis H; Campo JV
    Psychiatr Serv; 2018 Sep; 69(9):1015-1020. PubMed ID: 29962308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.